Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Shares of Omeros Corp. (OMER) are gaining almost 48 percent or $6.76 in Monday's morning trade at $20.89, after earlier touching a new 52-week high of $22.00 following positive data from a study evaluating Narsoplimab in the treatment of COVID-19 patients.


RTTNews | Aug 10, 2020 10:01AM EDT

10:00 Monday, August 10, 2020 (RTTNews.com) - Shares of Omeros Corp. (OMER) are gaining almost 48 percent or $6.76 in Monday's morning trade at $20.89, after earlier touching a new 52-week high of $22.00 following positive data from a study evaluating Narsoplimab in the treatment of COVID-19 patients.

Monday, the Seattle, Washington-based biopharmaceutical company reported the recovery and survival of all patients in a compassionate-use study evaluating Narsoplimab for the treatment of COVID-19-associated Acute Respiratory Distress Syndrome or ARDS.

Omeros noted that all six narsoplimab-treated patients, who required mechanical ventilation prior to the treatment, recovered, survived and were discharged from the hospital. The company said it is in discussions with U.S. government agencies regarding potential funding to accelerate the large-scale manufacturing of narsoplimab for use in COVID-19 patients.

Omeron has traded in a range of $8.50 to $22.00 in the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3120097/stock-alert-omeros-jumps-to-new-52-week-high-on-positive-narsoplimab-data.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC